An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Lucanthone (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 03 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Feb 2013 Planned number of patients changed from 140 to 210 as reported by ClinicalTrials.gov.
- 07 Aug 2012 New source identified and integrated (Clinical Trials Registry - India),